Chronic apical periodontitis (CAP) is a disease with characteristics of inflammation and bone loss. In this study, our objective was to examine the function of small extracellular vesicles (sEVs) obtained from milk in encouraging osteogenic differentiation and inhibiting inflammation by miR-21 in CAP. The expression of miR-21 was detected using qRT-PCR in human CAP samples. The impact of miR-21 on the process of osteogenic differentiation was investigated using CCK-8, qRT-PCR, immunofluorescence staining, and Western blot analysis. The evaluation of RAW 264.7 cell polarization and the assessment of inflammatory factor expression were conducted through qRT-PCR. The influence of sEVs on MC3T3-E1 cells and RAW 264.7 cells was examined, with a particular emphasis on the involvement of miR-21. In human CAP samples, a decrease in miR-21 expression was observed. MiR-21 increased the expression of osteogenesis-related genes and M2 polarization genes while decreasing the expression of M1 polarization genes and inflammatory cytokines. Treatment with milk-derived sEVs also promoted osteogenesis and M2 polarization while inhibiting M1 polarization and inflammation. Conversely, the addition of miR-21 inhibitors resulted in opposite effects. Our results indicated that sEVs derived from milk had a positive effect on bone formation and activation of anti-inflammatory (M2) macrophages and simultaneously reduced inflammation by regulating miR-21 in CAP.
24 June 2024 in International Journal of Biological Macromolecules
Small extracellular vesicles derived from milk (Milk-sEVs) have the advantages of easy availability, low cost, low toxicity, and inhibition of inflammation. CD36 mediates inflammation stress in a variety of disease states. The purpose of this study was to investigate the role of Milk-sEVs in inhibiting fibroblast inflammation through CD36 and provide reference data for the treatment of chronic apical periodontitis. The addition of Milk-sEVs resulted in decreased expression of inflammation-related factors in L929 cells, and transcriptome sequencing screened for the DEG CD36 in the Milk-sEV treatment group under inflammation. The mouse model of apical periodontitis was successfully established, and CD36 expression increased with the development of inflammation. Transfection of si-CD36 into L929 cells reduced inflammation by inhibiting activation of the MAPK signaling pathway. CD36 expression increased with the development of apical periodontitis. In the setting of LPS-mediated inflammation, Milk-sEVs inhibited activation of the MAPK signaling pathway by decreasing the expression of CD36 in L929 cells and thereby reducing inflammation.
Periodontitis is the number one cause of adult tooth loss worldwide. The main treatments for periodontitis are removed tartar, surgery, and medication, but none of them can bring about a cure. Traditional Chinese medicine as an adjunct to modulation of the host immune response in the treatment of periodontitis needs to be further researched and explored. This study investigated the effect of Hmong Medicine Tooth-fixing Formula (HM-TF) on periosteal bone repair in vivo and in vitro to provide an experimental basis for the use of the Hmong medicine in the clinical treatment of periodontitis. Screening of HM-TF and periodontitis co-action targets by network pharmacology analysis. The effects of HM-TF on the proliferation and differentiation of osteoblasts and osteoclasts were investigated by CCK-8 assay, Real-time qPCR, western blotting, ALP, alizarin red S, and TRAP staining. A rat periodontitis model was established, and micro-computed tomography (CT) and hematoxylin and eosin (HE) staining experiments were carried out to study the effect of HM-TF on bone repair and investigate its biosafety. The core active ingredients of HM-TF for treating periodontitis include quercetin, luteolin, kaempferol, etc. One of the main targets of HM-TF in periodontitis is RXRα, and all the active ingredients can effectively bind to RXRα. HM-TF enhanced the growth of osteoblasts by increasing the production of RXRα and factors related to bone formation. Additionally, it hindered the development of osteoclasts by reducing the expression of factors related to osteoclasts. Three-dimensional (3D) micro-CT, HE staining and immunohistochemical staining showed that HM-TF ameliorated the alveolar bone destruction caused by periodontitis in rats, and the effect was better than that of metronidazole. One of the main intersecting targets of HM-TF and periodontitis is RXRα. HM-TF promoted bone repair in rats with periodontitis and had good biocompatibility.
Objective: Icariin (ICA) is an active small molecule extracted from Epimedium, possessing therapeutic potential for inflammatory bone destruction. Small extracellular vesicles (MEVs) derived from bovine milk are safe and efficient drug delivery carriers. We aimed to explore the potential of ICA-loaded bovine milk EVs (ICA-MEVs) to repair inflammatory bone defects in an inflammatory microenvironment and investigated the underlying molecular mechanism, providing new ideas for the treatment of inflammatory bone defects. Methods: We fabricated icariin (ICA)-loaded milk-derived extracellular vesicles (ICA-MEVs) embedded in GelMA hydrogel and systematically evaluated the in vivo repairing efficacy against lipopolysaccharide (LPS)-induced inflammatory calvarial bone defects via micro-CT, HE staining, Masson staining and immunohistochemistry. Subsequent in vitro cellular experiments were carried out to uncover the regulatory mechanism by which ICA-MEVs promotes LPS-inhibited osteoblast proliferation and osteogenic differentiation. Results: ICA-MEVs significantly promoted the repair of inflammatory bone defects, upregulated osteogenic factors such as BMP-2, OCN, and Runx-2, and reduced the levels of IL-1β and TNF-α. ICA-loaded MEVs facilitated the proliferation and osteogenic differentiation of MC3T3-E1 osteoblasts while alleviating cellular inflammatory activation. Mechanistically, ICA-MEVs promoted bone repair by elevating LIM1 expression. Elevated LIM1 bound to the endogenous HIF-1α promoter and triggered subsequent transcriptional activation of HIF-1α. Conclusions: Under inflammatory conditions, ICA-MEVs effectively promoted the proliferation and differentiation of MC3T3-E1 cells and inhibited the expression of inflammatory factors. Mechanistically, ICA-MEVs upregulated HIF-1α transcription and expression by potentiating the LIM1-mediated transcriptional activation of the HIF-1α promoter, thereby facilitating inflammatory bone repair. Although milk-derived EVs exhibited favorable safety profiles in this preclinical study, comprehensive detection of immunogenicity and long-term adverse reactions will be necessary in follow-up research to support clinical transformation.
Apical periodontitis (AP), a localized inflammatory bone disease, and osteoporosis (OP), a systemic metabolic bone disorder, are both characterized by chronic inflammation and dysregulated bone metabolism, yet the molecular mechanisms underlying their association remain unclear. This study aimed to identify shared biomarkers and pathogenic pathways linking AP and OP. Gene expression datasets for AP and OP were obtained from the Gene Expression Omnibus database, and shared differentially expressed genes were identified and analyzed using functional enrichment, Gene set enrichment analysis (GSEA), Gene set variation analysis GSVA, and single-sample gene set enrichment analysis (ssGSEA)-based immune infiltration approaches. A random forest model was applied to prioritize candidate genes, followed by validation using single-cell RNA sequencing datasets, clinical samples, and in vitro assays. Forty-three shared differentially expressed genes were identified, among which FAM87B, ASCL2, and PACS1 were prioritized as candidate genes. PACS1 showed consistent upregulation in both AP and OP and was further validated in clinical samples. Integrated analyses suggested that shared molecular alterations were associated with NF-κB signaling and immune-metabolic dysregulation, while single-cell analysis supported PACS1 expression in cell subsets involved in inflammatory bone remodeling. Functionally, PACS1 knockdown promoted osteoblast differentiation, accompanied by increased ALP, RUNX2, and OPN expression. These findings suggest that PACS1 may serve as a shared candidate biomarker linking AP and OP and provide insight into immune-bone crosstalk in inflammatory bone loss.
Background: Inflammatory osteolysis features persistent inflammation and impaired bone formation, requiring therapeutics that concurrently suppress inflammation and promote osteogenesis. Ile-Arg-Trp (IRW), a bioactive tripeptide with anti-inflammatory and pro-osteogenic properties, suffers from poor cellular delivery. Milk-derived extracellular vesicles (MEVs) provide a biocompatible delivery platform to enhance intracellular bioavailability of IRW. We engineered IRW-functionalized MEVs (M-IRW), tested whether MEV delivery amplifies IRW’s dual bioactivity, and elucidated the molecular mechanism. Methods: The therapeutic effects of M-IRW were evaluated in LPS-stimulated MC3T3-E1 cells and a murine calvarial osteolysis model. Transcriptomic analysis and Geneformer-based virtual knockout identified candidate regulatory pathways, validated by gene silencing, rescue experiments, and reciprocal co-immunoprecipitation. A chronic apical periodontitis model assessed the disease relevance of this pathway. Results: Nano-flow cytometry and quantitative fluorescence analysis confirmed successful preparation and IRW loading of M-IRW, and M-IRW achieved enhanced cellular association with intracellular accumulation of the labeled IRW formulation relative to free peptide. In LPS-treated MC3T3-E1 cells, M-IRW more potently elevated ALP, RUNX2, and OPN expression than free IRW (p < 0.05). In vivo, M-IRW significantly enhanced osteogenic recovery in calvarial osteolysis, surpassing free IRW (p < 0.05). Transcriptomic analysis identified thioredoxin-interacting protein (Txnip) as a candidate mediator; virtual Txnip knockout predicted NRF2-associated transcriptional enrichment (p < 0.05). Depletion of NRF2 attenuated the osteogenic benefit conferred by both TXNIP knockdown and M-IRW treatment. Conclusions: M-IRW enables efficient intracellular delivery of IRW and promotes osteogenic repair in inflammatory osteolysis, at least partly through modulation of the TXNIP–NRF2 axis.